Rapamycin-13C, d3-1

Rapamycin-13C, d3-1 (Sirolimus-13C, d3-1) is the deuterium labeled and 13C-labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

Product Specifications

Product Name Alternative

Sirolimus-13C, d3-1; AY-22989-13C, d3-1

UNSPSC

12352005

Target

Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; Isotope-Labeled Compounds; mTOR

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

[H][C@@]1(N(CCCC1)C(C([C@]2([C@@H](CC[C@@](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C3=O)C)C)O[13C]([2H])([2H])[2H])(O2)[H])C)O)=O)=O)C(O[C@@](CC([C@@H](/C=C(C)/[C@H]([C@H]3OC)O)C)=O)([C@H](C)CC4(C[C@H]([C@@H](CC4)O)OC)[H])[H])=O

Molecular Formula

C50 13CH76D3NO13

Molecular Weight

918.18

References & Citations

[1]Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15 (2) :1811-1816.|[2]Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.|[3]Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30 (34) :11388-97.|[4]Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282 (18), 13395-13401.